Diabetes drug linked with reduced glaucoma risk

A commonly prescribed diabetes drug has been found to reduce the risk of open-angle glaucoma (OAG) in patients with diabetes.

Metformin hydrochloride is a medication used to help patients with type 2 diabetes manage their blood glucose levels. It mimics the effects of caloric restriction by inhibiting the release of stored glucose into the bloodstream by the liver.

Researchers from the University of Michigan and Indiana University in the US looked at data for 150,016 patients with diabetes, almost 4% of which (5,893) developed OAG.

Patients who received the highest dose of the metformin – more than 1,110g over a two-year period – saw a 25% reduction in their risk of developing the condition. This, write the researchers, predicts that taking a standard 2g dose of the drug every day for two years reduces the risk of OAG by 20.8%.

The researchers write: “This study suggests that metformin may be affecting OAG risk on multiple levels…If confirmed by prospective clinical trials, these findings could lead to novel treatments for this sight-threatening disease.”

The research is published in the journal JAMA Ophthalmology.

Recent Posts

Craig wins Myopia Management Award at the UK Optician Awards

Scotland’s largest Tomato Glasses stockist

MiSight 1 day range extended to -10.00D

How do Essilor Stellest lenses work?

Glaucoma Clinic – Craig McArthur to speak at Global Optometry Summit

Myopia control expert lectures at global conference

Stellest now available at Peter Ivins Eye Care

Myopia expert contributes to Optometry Today: A guide to myopia control

A guide to myopia control: Craig contributes to Optometry Today

Scotland’s first Oculus Myopia Master